Methadone Patient Access to Collaborative Treatment (MPACT) Study
This study, called Methadone Patient Access to Collaborative Treatment (MPACT), is testing a new program designed to improve methadone treatment for opioid use disorder. The MPACT program includes training for staff on patient-centered care and trauma, as well as education about trauma symptoms. The study aims to see if this program helps patients stay in methadone treatment longer and reduces overdose events. It also looks at how staff and patient experiences with trauma might affect the program's success. The study is currently recruiting staff who provide methadone treatment services at participating clinics.
- Study design
- This is a Hybrid Type 1, 15-month cluster randomized controlled trial involving 30 clinics, with 600 patients and 480 staff planned for enrollment.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Patient outcomes like days in treatment and missed doses will be measured up to 20 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Methadone Patient Access to Collaborative Treatment
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Days in Treatment to treatment interruption18 months
Time (days) to treatment interruption
- Missed doses20 months
Missed methadone doses in the last 30 days
- In Treatment- Point in time18 months
Point in time in treatment (0 day, 30 day, 60, day, 90 day)
- Number of patients reporting opioid overdoses while in methadone treatment18 months
Reported overdoses by patients in methadone treatment during the trial period by survey measured at 5 points during the study period.